Voronoi shares jumped 8% early on the 20th after news that phase 1 clinical trial results for its lung cancer targeted therapy "VRN11" beat market expectations.
As of 9:26 a.m., on the KOSDAQ market, Voronoi was trading at 333,000 won, up 26,000 won (8.47%) from the previous session.
Voronoi recently presented phase 1 results for VRN11 at the American Association for Cancer Research (AACR2026) meeting in San Diego. Partial response (PR), defined as at least a 30% reduction in tumor size, was confirmed in 7 of 8 patients with the EGFRC797S mutation in Non-small cell lung cancer (NSCLC), and the company said every patient dosed at 160 mg or higher achieved PR.
Consistent clinical benefit was also observed in patients unresponsive to existing targeted therapies. Based on patients who received an effective dose, the disease control rate (DCR) was 96.8%, and some patients were confirmed to have maintained long-term treatment for more than one year.
In addition, among patients treated across doses ranging from 10 mg to 480 mg, there was only one grade 3 or higher drug-related serious adverse event, supporting the safety profile.
Based on these results, Voronoi plans to initiate a phase 1b/2 cohort for patients with the EGFRC797S mutation within the year.
Ha Hyeon-su, an analyst at Yuanta Securities Korea, said, "We raised the development success probability for the C797S mutation indication of VRN11 from 44.1% to 66.2% and moved the launch timing up from 2029 to 2028," adding, "We also raised the success probability of VRN07 to 72.3%," and lifted the target price 41% to 450,000 won from 320,000 won.